Barry I Feinberg Net Worth

The estimated Net Worth of Barry I Feinberg is at least $551 Tysiąc dollars as of 14 August 2017. Barry Feinberg owns over 30,000 units of Biodelivery Sciences International stock worth over $550,615 and over the last 10 years Barry sold BDSI stock worth over $0.

Barry Feinberg BDSI stock SEC Form 4 insiders trading

Barry has made over 12 trades of the Biodelivery Sciences International stock since 2014, according to the Form 4 filled with the SEC. Most recently Barry exercised 30,000 units of BDSI stock worth $167,700 on 14 August 2017.

The largest trade Barry's ever made was exercising 30,000 units of Biodelivery Sciences International stock on 14 August 2017 worth over $167,700. On average, Barry trades about 9,000 units every 75 days since 2014. As of 14 August 2017 Barry still owns at least 98,500 units of Biodelivery Sciences International stock.

You can see the complete history of Barry Feinberg stock trades at the bottom of the page.

What's Barry Feinberg's mailing address?

Barry's mailing address filed with the SEC is 4131 Parklake Ave #225, Raleigh, NC 27612, USA.

Insiders trading at Biodelivery Sciences International

Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott oraz Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.

What does Biodelivery Sciences International do?

BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

Complete history of Barry Feinberg stock trades at Biodelivery Sciences International

Biodelivery Sciences International executives and stock owners

Biodelivery Sciences International executives and other stock owners filed with the SEC include:

• Scott Plesha,
  President, Chief Commercial Officer
• Mary Coelho,
  Chief Financial Officer, Treasurer
• Thomas Smith,
  Chief Medical Officer
• James Vollins,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Scott M. Plesha,
  Pres & Chief Commercial Officer
• James Vollins J.D.,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Dr. Thomas B. Smith FAAFP, M.D.,
  Chief Medical Officer
• Vanila Singh,
  Independent Director
• Mark Sirgo,
  Vice Chairman of the Board
• Todd Davis,
  Independent Director
• Peter Greenleaf,
  Independent Chairman of the Board
• William Watson,
  Independent Director
• Kevin Kotler,
  Independent Director
• Kevin Ostrander,
  Senior Vice President - Business Development
• Joseph Lockhart,
  Senior Vice President - Operations
• Jeffrey Bailey,
  Chief Executive Officer
• Dr. Jeff Katz,
  Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
• Dr. Arthur G. Lipman PharmD,
  Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
• Dr. Bill McCarberg,
  Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
• John Golubieski,
  CFO & Chief Accounting Officer
• Niraj Vasisht,
  Chief Technology Officer
• Samuel P Jr Sears,
  Director
• Barry I Feinberg,
  Director
• Charles Bramlage,
  Director
• William B Stone,
  Director
• Francis E Jr Odonnell,
  Director
• Thomas D'alonzo,
  Director
• Healthcare Master Fund Ltd ...,
  
• Timothy Tyson,
  Director
• W. Mark Watson,
  Director
• Kevin Broadfin Healthcare M...,
  
• Herm Cukier,
  Chief Executive Officer
• John J Shea,
  Director
• Iv Llc Ramsay David Russ Le...,
  
• Capital Group Ii Llc Hopkins,
  10% owner
• Allan Pearce,
  Director
• James R Butler,
  Director
• Paolantonio Ernest Robert De,
  CFO and Secretary
• Associates, L.P. Elliott,
  10% owner
• James A Mcnulty,
  Chief Financial Officer
• William Poole,
  Director
• Kathleen M Tr Irrev Tr 1 Fb...,
  10% owner
• Raphael J Mannino,
  Executive Vice President & CSO
• Donald Ferguson,
  Director
• Iv Llccdc Operations Llc Ra...,
  
• International, L.P. Elliott,
  10% owner
• L M Stephenson,
  Director
• Capital Group Llc Hopkins,
  10% owner
• Kathleen M O Donnell,
  10% owner
• Benny Ward,
  EVP of Busi. & Strategic Dev.
• John Golubieski,
  See Remarks